Investor desk
Investors should track partnership announcements and pipeline signals from AASLD.
← Back to Events
Tier 1 Global Networking: High HEPATOLOGY 106 DAYS AWAY
AASLD — 2026 — Denver, US
The Liver Meeting® 2026 - The 77th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 05-09 Nov 2026 | Conference Locate (Clocate) For event industry professionals #### Join Clocate's service providers network Showcase your services, reach qual
Presentation data updated Jul 22, 2026, 2:31 AM UTC
Why This Event Matters
The Liver Meeting® 2026 - The 77th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 05-09 Nov 2026 | Conference Locate (Clocate) For event industry professionals #### Join Clocate's service providers network Showcase your services, reach qualified clients, and grow your business with Clocate.
Industry impact
The Liver Meeting® 2026 - The 77th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 05-09 Nov 2026 | Conference Locate (Clocate) For event industry professionals #### Join Clocate's service providers network Showcase your services, reach qualified clients, and grow your business wi.
Market implications
Expect signals on pricing, formulary strategy, and partnership economics in US markets.
Regulatory implications
FDA and CMS policy on evidence generation and real-world data often surface at leadership forums.
Investor implications
Investors should track partnership announcements and pipeline signals from AASLD.
Competitive implications
Competitive positioning among hepatology players is a core theme — compare with prior editions.
Event Significance
Tier-1 industry catalyst
30 /100 composite
AASLD is a targeted hepatology forum where specialty pipeline readouts and BD conversations drive near-term positioning decisions. Primary driver: speaker calibre and KOL density.
- Speaker quality 14/20
Plenary and late-breaker slots attract global KOLs — high signal for clinical and regulatory teams.
- Company participation 0/20
Smaller exhibitor set — focus on disclosed presenters rather than floor traffic.
- Historical influence 10/20
Some historical catalysts; compare readouts against last cycle.
- Media coverage 6/20
Niche coverage — subscribe for direct abstract alerts.
- Pipeline relevance 0/20
Early science or services-focused — lower near-term PDUFA linkage.
Key Takeaways
Key Themes
hepatologyPipeline announcements
Key Markets
US Americas
Key Opportunities
Partnership dealsLicensing discussionsVendor selection
Timeline & Milestones
- Pre-event intelligence Upcoming
Abstract discovery in progress; monitor Key Data tab.
- Conference opens Nov 5, 2026 Upcoming
Live readouts, late-breakers, and partnership announcements.
- Live coverage window Upcoming
Nova editorial monitors confirmed data releases.
- Conference closes Nov 9, 2026 Upcoming
Post-event recap, competitive takeaways, and trial updates.
BD teams Investors & analysts Regulatory leaders
Executive Summary
C-level briefThe Liver Meeting® 2026 - The 77th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 05-09 Nov 2026 | Conference Locate (Clocate) For event industry professionals #### Join Clocate's service providers network Showcase your services, reach qualified clients, and grow your business wi
Primary audience: BD teams · Investors & analysts · Regulatory leaders
Analyst Watch
Regulatory affairs
FDA and CMS policy on evidence generation and real-world data often surface at leadership forums.
Competitive intelligence
Competitive positioning among hepatology players is a core theme — compare with prior editions.
Competitive Landscape
Company map →Competitive positioning among hepatology players is a core theme — compare with prior editions.
Coverage & Analysis
No coverage articles yet. Check back closer to the event.
Related News & Research
Research hub →Event Intelligence Summary
Standalone summaries for AASLD — optimized for research and AI retrieval.
Executive Summary
The Liver Meeting® 2026 - The 77th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 05-09 Nov 2026 | Conference Locate (Clocate) For event industry professionals #### Join Clocate's service providers network Showcase your services, reach qualified clients, and grow your business wi
Analyst View
The Liver Meeting® 2026 - The 77th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 05-09 Nov 2026 | Conference Locate (Clocate) For event industry professionals #### Join Clocate's service providers network Showcase your services, reach qualified clients, and grow your business wi
Investor View
Investors should track partnership announcements and pipeline signals from AASLD.
BD View
BD teams should prioritize partnership and licensing conversations at AASLD.
Key Facts
- Event
- AASLD
- Focus
- hepatology
- Region
- US Americas
- Location
- Denver, US
Ask Nova AI
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
Frequently Asked Questions
What is AASLD?
AASLD is a hepatology industry conference for executives, clinical leaders, and investors.
Who attends AASLD?
Typical attendees include pharma executives, BD teams, investors, and regulatory professionals focused on hepatology.
Why is AASLD important?
AASLD influences partnership timing and policy debates affecting hepatology markets for the next 12–18 months.
Where is AASLD held?
AASLD is held in Denver, US.
What should investors watch at AASLD?
Track partnership announcements, pipeline readouts, and management commentary on hepatology catalysts.
What BD opportunities exist at AASLD?
BD teams use AASLD for licensing, co-development, and vendor selection across hepatology.
How does AASLD compare with other pharma conferences?
AASLD is a tier-1 global congress for hepatology — compare with peer events in the same vertical.
How do I get NovaPharmaNews coverage of AASLD?
Subscribe to event alerts on this page for pre-event briefs, live coverage, and post-event analysis.